Domača stranAZN • STO
add
AstraZeneca
Prejšnji trg. dan.
1465,00 kr
Dnevni razpon
1445,00 kr - 1464,00 kr
Letni razpon
1261,00 kr - 1799,00 kr
Tržna kapitalizacija
160,68 mrd. GBP
Povprečni obseg
419,87 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
LON
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 13,56 mrd. | 18,04 % |
Stroški poslovanja | 7,79 mrd. | 4,64 % |
Čisti dohodek | 1,43 mrd. | 4,00 % |
Čista dobičkovnost prihodkov | 10,53 | −11,96 % |
Earnings per share | 1,04 | 20,23 % |
EBITDA | 4,63 mrd. | 45,69 % |
Efektivna davčna stopnja | 21,61 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 4,93 mrd. | −3,62 % |
Skupna sredstva | 104,92 mrd. | 9,20 % |
Skupne obveznosti | 64,12 mrd. | 8,92 % |
Celoten lastniški kapital | 40,80 mrd. | — |
Shares outstanding | 1,55 mrd. | — |
Razmerje P/B | 55,77 | — |
Donosnost sredstev | 7,92 % | — |
Donosnost kapitala | 11,38 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,43 mrd. | 4,00 % |
Denar iz dejavnosti | 3,38 mrd. | 8,64 % |
Denar iz naložb | −1,51 mrd. | −24,00 % |
Denar iz financiranja | −4,13 mrd. | −51,54 % |
Neto sprememba denarnih sredstev | −2,24 mrd. | −163,15 % |
Prost denarni tok | 2,05 mrd. | −12,38 % |
Vizitka
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, United Kingdom; Gothenburg, Sweden and Gaithersburg in Maryland, U.S.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
Generalni direktor
Datum ustanovitve
6. apr. 1999
Sedež organizacije
Spletno mesto
Zaposleni
89.900
